Table 3.

Results of the linear mixed effect model.

		PainDETECT high/low RCT group (n = 26)	PainDETECT high/low (n = 40)	FM +ve/−ve (n = 40)	Trapezius PPT below/above median (n = 40)	Facilitated TSP +ve/−ve (n = 32)	CPM responder/nonresponder (n = 40)
Unadjusted for preinjection NRS score	Group average	2.2 (0.3 to 4.2) P = 0.025	2.5 (0.9 to 4) P = 0.002	2.4 (1 to 3.8) P = 0.001	1.9 (0.6 to 3.3) P = 0.005	−1.6 (−4.0 to 0.8) P = 0.182	−0.7 (−2 to 0.6) P = 0.307
Adjusted for preinjection NRS score	Group average	0.5 (−0.9 to 1.8) P = 0.49	1.9 (0.8 to 3) P = 0.001	1.6 (0.3 to 2.9) P = 0.016	1.2 (0.0 to 2.4) P = 0.052	−1.6 (−3.4 to 0.3) P = 0.102	−0.2 (−1.2 to 0.8) P = 0.693

The table presents the difference in postinjection pain scores, represented as group averages accompanied by 95% confidence intervals. Initial results are provided without adjustments for preinjection pain NRS scores, followed by data that are adjusted for these scores. The first column displays outcomes from patients in the RCT, categorized based on their painDETECT high/low status. Subsequent columns show data from the second validation cohort (PUMIA), grouped not only by painDETECT high/low but also by other indicators of centrally mediated pain.

Entries highlighted in bold indicate significance at the 5% level.

RCT, randomized controlled trial; FM, fulfillment of fibromyalgia criteria; TSP, temporal summation of pain; CPM, conditioned pain modulation.